ストックスクリーナーアプリを入手
2.44
6.87%
-0.18
アフターアワーズ：
2.49
0.05
+2.05%
前日終値:
$2.62
開ける：
$2.7
24時間の取引高:
212.89K
Relative Volume:
0.96
時価総額：
$308.18M
収益：
-
当期純損益:
$-70.78M
株価収益率:
-4.3571
EPS:
-0.56
ネットキャッシュフロー:
$-61.27M
1週間 パフォーマンス:
+0.83%
1か月 パフォーマンス:
+20.79%
6か月 パフォーマンス:
+269.14%
1年 パフォーマンス:
+103.33%
1日の値動き範囲:
$2.425
$2.80
1週間の範囲:
$2.17
$2.80
52週間の値動き範囲:
$0.62
$3.08
Nautilus Biotechnology Inc Stock (NAUT) Company Profile
名前
Nautilus Biotechnology Inc
セクター
電話
206-333-2001
住所
2701 EASTLAKE AVE EAST, SEATTLE
Compare NAUT vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NAUT
Nautilus Biotechnology Inc
|
2.44 | 330.92M | 0 | -70.78M | -61.27M | -0.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Nautilus Biotechnology Inc Stock (NAUT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-05 | ダウングレード | Goldman | Neutral → Sell |
| 2024-06-27 | 開始されました | Guggenheim | Buy |
| 2024-06-03 | 再開されました | Jefferies | Hold |
| 2022-01-06 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-11-02 | 開始されました | Cowen | Outperform |
| 2021-08-04 | 開始されました | Goldman | Neutral |
| 2021-07-13 | 開始されました | Jefferies | Buy |
すべてを表示
Nautilus Biotechnology Inc (NAUT) 最新ニュース
Sujal Patel Buys 25,000 Shares of Nautilus Biotechnology (NASDAQ:NAUT) Stock - MarketBeat
Executive Parag Mallick receives 280,000 stock options at Nautilus (NAUT) - Stock Titan
Nautilus (NAUT) General Counsel receives 160,000-share stock option grant - Stock Titan
What’s the MACD signal for Nautilus Biotechnology Inc.2025 Winners & Losers & Safe Entry Point Identification - mfd.ru
Nautilus Biotechnology names Amber Faust as Vice President of Sales to drive proteomics expansion - Traders Union
NAUT: New proteomics platform promises comprehensive, reproducible protein analysis with broad applications - TradingView
Nautilus Biotechnology Appoints Proteomics Commercial Leader Amber Faust as Vice President of Sales - BioSpace
Nautilus Biotechnology appoints Amber Faust as VP of sales By Investing.com - Investing.com India
Nautilus Biotechnology appoints proteomics commercial leader Amber Faust as vice president of sales - marketscreener.com
Nautilus Biotechnology appoints Amber Faust as VP of sales - Investing.com
Sales veteran joins Nautilus to push single-molecule proteomics into labs - Stock Titan
Guggenheim Forecasts Strong Price Appreciation for Nautilus Biotechnology (NASDAQ:NAUT) Stock - Defense World
Aug Big Picture: What are PROFs growth levers2025 EndofYear Setup & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
NAUT Should I Buy - Intellectia AI
Nautilus Biotechnology (NAUT) Target Price Raised by Guggenheim - GuruFocus
Nautilus debuts Voyager platform in push toward next-gen proteomics - Longevity.Technology
Nautilus Biotechnology (NASDAQ:NAUT) Price Target Raised to $4.00 at Guggenheim - MarketBeat
Nautilus Biotechnology (NAUT) Target Price Raised by Guggenheim | NAUT Stock News - GuruFocus
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q4 2025 Earnings Call Transcript - Insider Monkey
Nautilus Biotechnology stock price target raised to $4 by Guggenheim - Investing.com Canada
Nautilus (NAUT) Q4 2025 Earnings Call Transcript - The Globe and Mail
Nautilus Biotechnology, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Nautilus Biotechnology Q4 Earnings Call Highlights - MarketBeat
Nautilus projects 15%-20% expense growth in 2026 as early access program ramps up - MSN
Nautilus Biotechnology (NASDAQ:NAUT) Announces Earnings Results - MarketBeat
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2025 Financial Results - Investing News Network
Earnings call transcript: Nautilus Biotechnology Q4 2025 shows cost cuts By Investing.com - Investing.com Australia
Earnings call transcript: Nautilus Biotechnology Q4 2025 shows cost cuts - Investing.com Nigeria
BRIEF-Nautilus Biotechnology Q4 EPS USD -0.11 - TradingView
Nautilus Biotechnology Inc. recently stated that the company does not expect to generate substantial revenue from early access program collaborations before 2026. - Bitget
Nautilus Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Nautilus Biotechnology Q4 2025 Earnings Call Transcript - MarketBeat
Market Fear: Whats the RSI of Nautilus Biotechnology Inc stockMarket Risk Report & Capital Protection Trade Alerts - baoquankhu1.vn
Nautilus Biotechnology (NAUT) trims 2025 loss, sees cash runway through 2027 - Stock Titan
Nautilus Biotechnology Unveils Voyager Platform, Enabling Single-Molecule Iterative Mapping, at US HUPO 2026 - BioSpace
Nautilus Biotechnology IncCommercial launch of Voyager platform expected in late 2026 - marketscreener.com
Nautilus Biotechnology, Inc. Unveils Voyager Platform, Enabling Single-Molecule Iterative Mapping, At US HUPO 2026 - marketscreener.com
Nautilus machine maps 10 billion proteins to study Alzheimer’s - Stock Titan
Ideas Watch: Does Nautilus Biotechnology Inc have a competitive edge2025 Geopolitical Influence & AI Driven Price Forecasts - baoquankhu1.vn
Nautilus Biotechnology (NAUT) to Release Earnings on Thursday - Defense World
Is Nautilus Biotechnology Inc. stock a smart retirement pickMarket Performance Recap & Technical Pattern Alert System - mfd.ru
Nautilus Biotechnology to Participate in the TD Cowen 46th Annual Health Care Conference - Bluefield Daily Telegraph
Short Interest in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Decreases By 16.6% - MarketBeat
Will Nautilus Biotechnology Inc. stock hit new highs in YEARWeekly Trend Recap & Proven Capital Preservation Tips - mfd.ru
Pullback Watch: Should I hold or sell Nautilus Biotechnology Inc nowTrade Signal Summary & Real-Time Market Sentiment Reports - baoquankhu1.vn
How Nautilus Biotechnology Inc. stock reacts to job market data2025 Risk Factors & Daily Volume Surge Signals - mfd.ru
3 Penny Stocks With Market Caps Over $50M To Watch - simplywall.st
Earnings Miss: Does Nautilus Biotechnology Inc have strong fundamentalsStop Loss & Real-Time Buy Signal Notifications - baoquankhu1.vn
Nautilus Biotechnology explores multiomics to mitigate space travel effects - Traders Union
Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 - The Manila Times
Risk Hedge: Is GP Act III Acquisition Corp Equity Warrant stock suitable for long term investing - baoquankhu1.vn
Nautilus Biotechnology Inc (NAUT) 財務データ
収益
当期純利益
現金流量
EPS
3.69%
0.68%
大文字化:
|
ボリューム (24 時間):